Recognition of T2-high asthma relies on biomarkers such as blood and sputum EOS counts, FeNO, and often IgE overproduction (in atopic endotype), while treatment focuses on ICS-LABA MART regimens and specific add-ons depending on clinical presentation, such as maintenance OCSs or MAbs targeting key cytokines (e.g., IL-4, IL-5/5R, and TSLP). This evidence concerns the gene IL4 and asthma.